Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-24 4:16 pm Purchase |
2025-02-14 | 13G | Aardvark Therapeutics, Inc. Common Stock AARD |
Decheng Capital Global Life Sciences Fund IV, L.P. | 3,917,299 18.300% |
3,917,299 (New Position) |
Filing History |
| 2025-02-14 5:40 pm Purchase |
2024-12-31 | 13G | CG Oncology, Inc. Common stock CGON |
Decheng Capital Global Life Sciences Fund IV, L.P. | 6,371,669 8.400% |
912,859 (+16.72%) |
Filing History |
| 2025-02-14 5:38 pm Purchase |
2024-12-31 | 13G | Upstream Bio, Inc. UPB |
Decheng Capital Global Life Sciences Fund IV, L.P. | 3,285,293 6.100% |
3,285,293 (New Position) |
Filing History |
| 2024-04-09 7:12 pm Purchase |
2024-01-29 | 13G | CG Oncology, Inc. Common stock CGON |
Decheng Capital Global Life Sciences Fund IV, L.P. | 5,458,810 8.200% |
400,000 (+7.91%) |
Filing History |
| 2024-02-08 5:17 pm Purchase |
2024-01-29 | 13G | CG Oncology, Inc. Common stock CGON |
Decheng Capital Global Life Sciences Fund IV, L.P. | 5,058,810 7.600% |
5,058,810 (New Position) |
Filing History |
| 2021-02-16 5:21 pm Purchase |
2021-02-05 | 13D | Equillium, Inc. EQ |
Decheng Capital Global Life Sciences Fund IV, L.P. | 5,733,021 19.700% |
5,733,021 (New Position) |
Filing History |